) expanded its suite of TruSight content sets by adding TruSight
Tumor to its portfolio. TruSight's content set is created
according to different diseases. Inherited disease, exome,
cardiomyopathy, cancer and autism form an important part of
TruSight's content set.
This new product is capable of detecting different types of
tumors in the body including melanoma, colon, lung, ovary and
gastric cancer. This product will enable somatic variant
detection in solid tumors by running on Illumina's popular MiSeq
TruSight Tumor, in an economic way, provides exhaustive
solutions on tumor heterogeneity in comparison with the
gene-based methods. The researchers can also identify physical
changes in multiple genes across the tumor genome.
Explaining the heterogeneity approach, the company said that
TruSight Tumor is equipped with technology that would not miss a
single candidate for targeted therapy, which could have been
missed under single gene approach. With restricted DNA input,
TruSight Tumor has the capability for allele detection.
Illumina is due to report its first quarter 2013 results on
Apr. 22, 2013. The Zacks Consensus Estimate of EPS for the
quarter stands at $0.38. ILMN has beaten the Zacks Consensus
earnings estimate in three out of past four quarters. Currently,
Illumina carries a Zacks Rank #4 (Sell). This California-based
company develops, manufactures, and markets life science tools
and integrated systems for the analysis of genetic variation and
function on a broader scale.
Additionally, Illumina provides medium for further development
in consumer genomics and diagnostics. The company's products and
technology transforms healthcare through advanced genetic
analysis research and its application.
Other medical products companies worth considering are
Biogen Idec Inc.
Cleveland BioLabs, Inc.
), all which carry a Zacks Rank #1 (Strong Buy).
BIOGEN IDEC INC (BIIB): Free Stock Analysis
CLEVELAND BIOLB (CBLI): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis
XOMA CORP (XOMA): Free Stock Analysis Report
To read this article on Zacks.com click here.